Samsung Biologics announces all-cash offer to acquire PolyPeptide, accelerating multi-modality strategy and expanding global network across U.S., Europe, and India
Samsung Biologics to launch an all-cash public tender offer for 100% of PolyPeptide's fully diluted share capital (excluding therefrom any treasury shares) at CHF 44.31 per share, representing an equity value of approximately CHF 1.46 billion....
Samsung Biologics Releases 2026 ESG Report, Highlighting Progress in Sustainable Operations and Responsible Growth
Advanced environmental performance through renewable energy transition and enhanced carbon transparency Strengthened sustainability management and supply chain engagement across the healthcare value chain INCHEON, South Korea, June 30, 2026...
Frost & Sullivan Institute Celebrates Visionary Companies Addressing the World's Most Pressing Challenges
SILICON VALLEY, Calif., June 16, 2026 /PRNewswire/ -- The Frost & Sullivan Institute is pleased to present the 2026 Visionary Growth Leadership Best Practices Recognition, celebrating leading enterprises that are redefining the role of business...
Samsung Biologics Listed on Dow Jones Best-in-Class World Index for Fifth Consecutive Year
Marks five consecutive years of inclusion, reflecting continued progress in ESG management and execution Recognition highlights proactive alignment with evolving expectations from global stakeholders INCHEON, South Korea, May 5, 2026 /PRNewswire/ --...
Samsung Biologics Reports First Quarter 2026 Financial Results
Recorded Q1'26 revenue of KRW 1,257 billion and operating profit of KRW 581 billion Performance driven by full utilization across Plants 1 through 4 and robust operational execution Strengthened the foundations for future growth through U.S....
Samsung Biologics completes acquisition of GSK's manufacturing facility in Rockville, Maryland
Adds 60,000 liters of drug substance capacity, bringing the total to 845,000 liters Marks Samsung Biologics' geographical diversification and establishes its first U.S. manufacturing presence, expanding regional client support Plans further...
Samsung Biologics Recognized for Advancing Sustainability at 2026 CDMO Leadership Awards
Reinforcing long-term commitment to embedding sustainability across operations and partnerships Continuing to support clients in delivering high-quality, life-saving medicines to patients worldwide INCHEON, South Korea, March 26, 2026 /PRNewswire/...
Samsung Biologics leads climate transparency with independent validation of Product Carbon Footprint system
Samsung Biologics' PCF system validated in line with globally established ISO and PAS standards Validation reflects continued efforts to establish credible carbon accounting in support of net-zero goals Validated system provides reliable, consistent...
CEPI and Samsung Biologics collaborate to strengthen outbreak-ready vaccine production and global access
OSLO, Norway and INCHEON, South Korea, Feb. 3, 2026 /PRNewswire/ -- The Coalition for Epidemic Preparedness Innovations (CEPI) and Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today...
Samsung Biologics receives EcoVadis Platinum, the highest sustainability rating
Ranked in the top one percent among more than 150,000 companies assessed globally Recognized for strengthened sustainability management across all four assessment categories INCHEON, South Korea, Jan. 28, 2026 /PRNewswire/ -- Samsung Biologics (KRX:...